MedTrace Logo

GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer

NCT06111105 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 590

Last updated 2026-05-04

No results posted yet for this study

Summary

Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for colorectal cancer, the methods used to decide who gets additional post-surgery treatment are suboptimal. Some patients get too much treatment, while others do not get enough.

There is a new way to explore if there is any cancer left in a patient's body using circulating tumor DNA (ctDNA) detected in blood samples. This can help decide who needs more treatment after surgery. Even though many tests have been developed, it has yet to be determined which test performs best at relevant time points.

The GUIDE.MRD consortium is a group of experts, including scientists, technology, and pharmaceutical companies. The consortium is working on creating a reliable standard for the ctDNA tests, validating their clinical utility, and collecting data to help decide on the best treatment for each patient.

GUIDE.MRD-01-CRC is a part of the GUIDE.MRD project.

Conditions

  • Colorectal Cancer Stage III
  • Liver Metastasis Colon Cancer

Sponsors & Collaborators

  • Medical University of Graz

    collaborator OTHER

  • University Medical Centre of Montpellier

    collaborator UNKNOWN

  • Universitätsklinikum Hamburg-Eppendorf

    collaborator OTHER

  • University of Aarhus

    collaborator OTHER

  • Karolinska Institutet

    collaborator OTHER

  • Claus Lindbjerg Andersen

    lead OTHER

Principal Investigators

  • Ellen Heitzer, PhD · Medical University of Graz

  • Klaus Pantel, MD · Universitätsklinikum Hamburg-Eppendorf

  • Catherine Alix-Panabiéres, PhD · University Medical Centre of Montpellier

  • Matthias Löhr, MD · Karolinska Institutet

  • Claus L Andersen, PhD · Aarhus University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2026-07-31
Completion
2031-07-31

Countries

  • Austria
  • Denmark
  • France
  • Germany
  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06111105 on ClinicalTrials.gov